Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
D. Subhas Bose & Nukala Ramesh. (2020) A convenient access to 2,4-disubstituted quinazolines via one-pot three-component reaction under mild conditions†. Synthetic Communications 50:10, pages 1495-1503.
Read now
Read now
Bassam M. Ayoub, Yasmeen M. Attia & Mahmoud S. Ahmed. (2018) Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular carcinoma. Journal of Enzyme Inhibition and Medicinal Chemistry 33:1, pages 858-866.
Read now
Read now
Baptist Gallwitz. (2017) A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes. Expert Opinion on Drug Safety 16:12, pages 1399-1405.
Read now
Read now
Baptist Gallwitz. (2015) Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin. Therapeutics and Clinical Risk Management 11, pages 799-805.
Read now
Read now
Theodosios D Filippatos, Vasilios G Athyros & Moses S Elisaf. (2014) The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 787-812.
Read now
Read now
George Grunberger. (2013) Clinical Utility of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin. Postgraduate Medicine 125:3, pages 79-90.
Read now
Read now
Thomas Forst & Andreas Pfützner. (2013) Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus. Expert Review of Endocrinology & Metabolism 8:1, pages 21-35.
Read now
Read now
Lene Hoimark, Torben Laursen & Jørgen Rungby. (2012) Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 5, pages 295-302.
Read now
Read now
Articles from other publishers (22)
Qing Li, Xiaoyan Deng, Yan-Jun Xu & Lin Dong. (2023) Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants. Journal of Medicinal Chemistry 66:17, pages 11593-11631.
Crossref
Crossref
Matilda Florentin, Michael S Kostapanos & Athanasia K Papazafiropoulou. (2022) Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. World Journal of Diabetes 13:2, pages 85-96.
Crossref
Crossref
Jean-Luc Décout. 2022. Comprehensive Heterocyclic Chemistry IV. Comprehensive Heterocyclic Chemistry IV
419
499
.
Paola Di Matteo, Martina Bortolami, Marta Feroci, Vincenzo Scarano & Rita Petrucci. (2021) Electrochemical Transformations of Methylxanthines in Non‐Aqueous Medium. ChemElectroChem 8:15, pages 2754-2763.
Crossref
Crossref
Maurice Dörr, Johannes L. Röckl, Jonas Rein, Dieter Schollmeyer & Siegfried R. Waldvogel. (2020) Electrochemical C−H Functionalization of (Hetero)Arenes—Optimized by DoE. Chemistry – A European Journal 26:45, pages 10195-10198.
Crossref
Crossref
A Lakshmana Rao, T. Prasanthi & E. L Anusha. (2019) RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF LINAGLIPTIN AND EMPAGLIFLOZIN. INDIAN DRUGS 56:05, pages 68-71.
Crossref
Crossref
Taku Koyama, Atsushi Tanaka, Hisako Yoshida, Jun-ichi Oyama, Shigeru Toyoda, Masashi Sakuma, Teruo Inoue, Yoritaka Otsuka & Koichi Node. (2018) Comparison of the effects of linagliptin and voglibose on endothelial function in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, pilot study (EFFORT). Heart and Vessels 33:8, pages 958-964.
Crossref
Crossref
Yanqing Zhang, Genevieve E Fava, Meifen Wu, Wynn Htun, Thomas Klein, Vivian A Fonseca & Hongju Wu. (2017) Effects of Linagliptin on Pancreatic α Cells of Type 1 Diabetic Mice. Journal of the Endocrine Society 1:10, pages 1224-1234.
Crossref
Crossref
Yanqing Zhang, Meifen Wu, Wynn Htun, Emily W. Dong, Franck Mauvais-Jarvis, Vivian A. Fonseca & Hongju Wu. (2017) Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors. Scientific Reports 7:1.
Crossref
Crossref
Paola Gordillo Guerra, Paolo Clerici & Laurent Micouin. (2017)
Modular Access to N-Substituted
cis
5-Amino-3-hydroxypiperidines
. The Journal of Organic Chemistry 82:14, pages 7689-7694.
Crossref
Crossref
Antonio Ceriello & Nobuya Inagaki. (2017) Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations. Journal of Diabetes Investigation 8:1, pages 19-28.
Crossref
Crossref
Yanwei Li, Lin Li & Christian Hölscher. (2016) Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. Reviews in the Neurosciences 27:7, pages 689-711.
Crossref
Crossref
Xueying Tan & Jingbo Hu. (2016) Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes. Annales d'Endocrinologie 77:5, pages 557-562.
Crossref
Crossref
M. Nauck. (2016) Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors. Diabetes, Obesity and Metabolism 18:3, pages 203-216.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:10, pages 999-1024.
Crossref
Crossref
Thomas Haak. (2015) Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes. Clinical Medicine Insights: Endocrinology and Diabetes 8, pages CMED.S10360.
Crossref
Crossref
Ulrike Graefe-Mody, Christian FriedrichMaximilian von Eynatten, Sandra Thiemann, Tim Heise & Hans-Juergen Woerle. (2014)
Letter to the editor regarding: “Pharmacokinetics of teneligliptin in subjects with renal impairment.” Halabi
et al
.,
Clinical Pharmacology in Drug Development
2013;2:246-254
. Clinical Pharmacology in Drug Development 3:5, pages 417-418.
Crossref
Crossref
E. Kutoh. (2014) Probable linagliptin-induced liver toxicity: A case report. Diabetes & Metabolism 40:1, pages 82-84.
Crossref
Crossref
Erika Paniago Guedes, Alexandre Hohl, Thais Gomes de Melo & Felipe Lauand. (2013) Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment. Diabetology & Metabolic Syndrome 5:1.
Crossref
Crossref
Jürgen Sandow. 2013. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays
421
520
.
Chrysi Koliaki & John Doupis. (2012) Linagliptin/Metformin Fixed-Dose Combination Treatment: A Dual Attack to Type 2 Diabetes Pathophysiology. Advances in Therapy 29:12, pages 993-1004.
Crossref
Crossref
F. Palmer, S.L. Prior, A. Mallipedhi, D.A. Jones, D.E. Price & J.W. Stephens. (2012) Treatment choices for managing hyperglycaemia in patients with type 2 diabetes and moderate to severe renal disease. Diabetes Research and Clinical Practice 97:2, pages e23-e24.
Crossref
Crossref